Welcome to our dedicated page for XOMA Royalty Corporation SEC filings (Ticker: XOMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
XOMA Royalty Corporation (Nasdaq: XOMA) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its royalty aggregation business, capital structure, and transaction activity. On this page, you can review XOMA Royalty’s SEC filings alongside AI-powered summaries that help explain the key points in accessible language.
For investors analyzing XOMA Royalty, Form 10-K annual reports and Form 10-Q quarterly reports provide detail on royalty and milestone receipts, portfolio composition, risk factors, and accounting for acquired economic interests. Form 8-K current reports document material events such as the completion of acquisitions of HilleVax, LAVA Therapeutics, and Mural Oncology, entry into at-the-market sales agreements for common and preferred stock, and announcements of financial results.
XOMA Royalty’s filings also describe its listed securities, including common stock (XOMA) and preferred instruments such as 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) and depositary shares representing 8.375% Series B Cumulative Perpetual Preferred Stock (XOMAO). Related registration statements and prospectus supplements outline how proceeds from these offerings may be used to acquire additional potential royalty and milestone revenue streams, fund preferred dividends, and support general corporate purposes.
In addition, Form 4 insider transaction reports and proxy materials can provide insight into equity ownership and governance, while exhibits to 8-K filings include key agreements such as merger agreements, share purchase agreements, contingent value rights agreements, and sales agreements. Stock Titan’s interface enhances these filings with AI-generated highlights that point out important terms, transaction structures, and potential implications for XOMA Royalty’s royalty and milestone portfolio, helping readers navigate complex legal and financial disclosures more efficiently.
XOMA Royalty Corp filed an initial insider ownership report for Chief Financial Officer Jeffrey Trigilio. The Form 3 indicates that, at the time of this filing, no securities of XOMA Royalty Corp are beneficially owned. The form is filed by one reporting person, reflecting his role as an officer and providing a baseline disclosure of his current holdings status.
XOMA Royalty Corporation, through its subsidiary XRA 7 Corp., is conducting a tender offer to acquire all outstanding shares of Generation Bio Co. (GBIO) common stock. Each share is being offered $4.2913 in cash, without interest and less any applicable tax withholding, plus one non-tradable contingent value right (CVR) that may provide additional cash payments under a CVR agreement.
This amendment updates only the timing of the offer. The expiration has been changed from one minute after 11:59 p.m. Eastern Time on February 8, 2026 to one minute after 11:59 p.m. Eastern Time on February 6, 2026. All other terms and conditions of the tender offer remain the same as previously described in the offer materials.
XOMA Royalty Corporation filed a current report to let investors know it has made an updated corporate presentation available as of January 12, 2026. The presentation is attached as Exhibit 99.1 and is intended to provide refreshed information about the company.
The company specifies that the material in Item 7.01, including the presentation, is being furnished rather than filed, meaning it is not subject to certain Exchange Act liability provisions and is not automatically incorporated into other SEC filings unless specifically referenced.
XOMA Royalty Corporation and its wholly owned subsidiary XRA 7 Corp. plan to launch a cash tender offer to acquire all issued and outstanding shares of common stock of Generation Bio Co. under an Agreement and Plan of Merger dated December 15, 2025. The communication explains that the offer has not yet commenced and that full terms will be provided in formal tender offer materials on Schedule TO and a related Schedule 14D-9 recommendation statement to be filed with the SEC.
It also contains extensive forward-looking statements and risk disclosures, noting that the transactions may be delayed or may not close due to factors such as competing offers, the level of stockholder tenders, legal proceedings, failure to satisfy closing conditions, possible termination of the merger agreement and uncertainty around any contingent value rights payments to Generation Bio stockholders.
Owen Hughes, Chief Executive Officer and director of XOMA Royalty Corp, reported acquiring 100,000 depositary shares of the company’s 8.375% Series B cumulative preferred stock on 12/04/2025 at $25.05 per share. After this transaction, he beneficially owns 102,000 of these depositary shares directly, along with 98,268 common shares held directly and 295 common shares held through a 401(k) plan.
XOMA Royalty Corporation completed its acquisition of Mural Oncology plc on December 5, 2025, via an Irish High Court–sanctioned scheme of arrangement. Under the transaction agreement, Mural shareholders are entitled to receive a cash price of $2.035 per share. Outstanding Mural stock options were canceled at closing and converted into the right to receive cash equal to the per‑share consideration minus the option exercise price, while options with exercise prices at or above $2.035 received no payment. Outstanding restricted stock units were canceled and converted into the right to receive cash equal to the $2.035 per‑share consideration. XOMA plans to file audited Mural financial statements and unaudited pro forma combined financial information for XOMA and Mural in a later amendment.
XOMA Royalty Corporation has completed its acquisition of LAVA Therapeutics N.V. through a tender offer and subsequent reorganization. XOMA offered LAVA shareholders $1.04 in cash per share plus one non-transferable contingent value right (CVR) for each common share, with each CVR providing the right to potential future cash payments under a CVR Agreement. After the subsequent offering period expired on November 20, 2025, XOMA and LAVA completed a post-offer reorganization in which remaining minority shareholders ceased to hold LAVA shares and will receive the same mix of cash and CVRs as in the offer. XOMA also announced these steps in a November 21, 2025 press release and plans to file LAVA’s historical financial statements and pro forma combined financials in a later amendment.
LAVA Therapeutics (LVTX) reported the completion of XOMA Royalty Corporation’s tender offer and post-offer reorganization. As of the subsequent closing date, a total of 23,956,708 common shares, representing approximately 91.1% of LAVA’s outstanding shares, were validly tendered and accepted for payment, including 1,079,245 shares (about 4.2%) tendered during the subsequent offering period. The shares ceased trading on Nasdaq prior to the opening on November 21, 2025, and Nasdaq will file a Form 25 to delist and deregister the shares. LAVA and XOMA plan to file Form 15 to terminate registration and suspend LAVA’s reporting obligations, completing LAVA’s transition to a non-reporting, privately held company structure.
LAVA Therapeutics (LVTX) reported the tender offer by XOMA Royalty Corporation expired one minute after 11:59 p.m. ET on November 12, 2025, with 22,877,463 shares tendered, representing approximately 86.9% of outstanding shares. Purchaser intends to accept and promptly pay for all validly tendered shares.
A Subsequent Offering Period of five business days runs from November 13, 2025 until one minute after 11:59 p.m. New York City time on November 20, 2025. The offer consideration is $1.04 in cash per share plus one non‑transferable CVR per share.
Following the Subsequent Offering Period, the purchaser expects to complete a Post‑Offer Reorganization, after which LAVA will cease to be publicly traded and its NASDAQ listing will be terminated. Shareholders who did not tender and are cashed out in the reorganization will receive the same consideration, subject to Dutch dividend withholding tax (15%) on the portion exceeding the recognized paid‑up capital, while no Dutch dividend withholding tax applies to amounts paid for shares tendered in the offer.
XOMA Royalty Corporation furnished an 8-K announcing it issued a press release covering financial results for the fiscal quarter ended September 30, 2025. The release is provided as Exhibit 99.1 and highlights third‑quarter and year‑to‑date 2025 performance and recent business achievements.
The company stated that the information in this report and Exhibit 99.1 is not deemed “filed” under the Exchange Act, limiting potential Section 18 liabilities and incorporation by reference unless specifically referenced.